DOCSLIB.ORG

Levomilnacipran Inhibits Both Norepinephrine and Serotonin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Levomilnacipran Inhibits Both Norepinephrine and Serotonin Levomilnacipran Inhibits Both Norepinephrine and Serotonin Reuptake Across the Clinical Dose Range Joann O’Connor | Laishun Chen | Carl Gommoll | Pradeep Banerjee | Stephen Zukin Forest Research Institute, Jersey City, NJ, USA INTRODUCTION METHODS Dysfunction of the norepinephrine (NE) and serotonin (5-HT) systems Pharmacokinetic Analyses CONCLUSIONS is thought to play a central role in the etiology and pathophysiology of PK data were collected from adult patients with MDD who major depressive disorder (MDD). Some symptoms of depression, such as Cmax and AUC of levomilnacipran are linear and proportional participated in a positive 8-week placebo-controlled, fixed-dosed trial anxiety, agitation, and irritability, have been more closely associated with 6 in the approved dose range of 40-120 mg/day; the median 5-HT while other depressive symptoms, such as fatigue, lack of motivation, Tmax is 6 hours in patients with MDD 1 and decreased concentration, appear to be more strongly related to NE. Approximately 15% of patients in each levomilnacipran ER dose group In plasma, once-daily levomilnacipran ER administration Effective treatment options for MDD include the serotonin-norepinephrine consented to give serial blood samples after the first 4 weeks of double- is expected to result in concentrations that will inhibit NE reuptake inhibitors (SNRIs) duloxetine, venlafaxine, and desvenlafaxine. blind treatment and 5-HT reuptake more than 90% and 80%, respectively, Blood samples were collected predose and at 2, 4, 6, 8, 12, and 24 hours across the 24-hour dosing interval and approved dose range of 5-HT relative to NE and studies have suggested that duloxetine and 2-4 postdose venlafaxine may only inhibit NE reuptake in patients at higher doses. 5-HT reuptake inhibition may be achieved at all 3 clinically Plasma samples were analyzed using a validated liquid chromatography- In contrast, levomilnacipran, a potent and selective SNRI, shows greater approved levomilnacipran ER doses (40, 80, 120 mg/day) 5 tandem mass spectrometry method; PK analysis was performed using potency in vitro for the inhibition of NE reuptake relative to 5-HT reuptake. Phoenix WinNonlin (Ver 6.1) Inhibition of both NE and 5-HT across the approved dose Levomilnacipran extended-release (ER) was recently approved for the Unbound plasma concentrations were estimated based on the previously duloxetine and venlafaxine, which may only show clinically 10 was established in 3 phase III studies.6-8 Long-term safety was supported determined levomilnacipran plasma protein binding value of 22% meaningful NE reuptake inhibition at higher doses by a 48-week open label study.9 Estimation of Clinical NE and 5-HT Reuptake Inhibition profile of levomilnacipran ER 40, 80, and 120 mg/day in patients with Conventional plasma concentration units (ng/mL) of levomilnacipran were Estimated NE and 5-HT Reuptake Inhibition MDD and use the PK data to estimate NE and 5-HT reuptake inhibition converted to molar concentration (nM) units to allow for comparison to Following multiple-dose administration, the average unbound plasma over the levomilnacipran ER dose range. in vitro NE and 5-HT reuptake inhibition results concentrations for levomilnacipran that were reached in MDD patients Unbound plasma concentrations were obtained over a 24-hour period from treated with levomilnacipran ER 40, 80, or 120 mg/day exceeded the concentration that showed 90% inhibition of NE (Figure 4) and plotted against time BACKGROUND Mean unbound levomilnacipran levels exceeded the estimated IC90 To evaluate how these plasma concentrations compared to concentrations values for NE reuptake inhibition for the entire 24-hour dosing period by Auclair et al5 that inhibited NE and 5-HT reuptake in vitro (human recombinant Figure 4. Levomilnacipran Plasma Unbound Concentration transporters), the recalculated IC50, IC80, and IC90 values from the Auclair a Compared to In Vitro NE Reuptake Inhibition (IC) Values et al study published in 20135 (see background) were superimposed on experiments5 and inhibition dose curves were plotted (Figure 1) the graph Levomilnacipran showed greater potency for inhibiting NE reuptake compared with 5-HT reuptake, with IC50 values of 10 nM and 18 nM, respectively ) M 100 n IC90 ( n o IC i 80 80 90 In vitro, the levomilnacipran IC and IC values were estimated to be RESULTS t a r t Pharmacokinetic Profile n 39 nM and 86 nM, respectively, for the NE reuptake transporter, and e c 10 IC50 n o 88 nM and 232 nM, respectively, for the 5-HT reuptake transporter C max ) were 92.8, 180.4 , and a m s a 297.2 ng/mLfor the 40-, 80-, and 120-mg doses, respectively (Table 1) l Figure 1. In Vitro 5-HT and NE Reuptake Inhibitory Profles of P 1 a Levomilnacipran 40 mg/day (Tmax) was 6 hours 80 mg/day 120 mg/day 120 for all 3 doses 5-HT 0 NE 0 5 10 15 20 25 Time (h) Reuptake Inhibition a 5 100 to 24 hours (AUC0-τ) were 1519.8, 2934.9, and 4798.5 h*ng/mL for NE reuptake inhibition was estimated using in vitro data (CHO cells expressing hNET) from Auclair et al. 5-HT NE IC50 (nM) 18 10 levomilnacipran ER 40, 80, and 120 mg/day, respectively IC80 (nM) 88 39 IC90 (nM) 232 86 80 min) at steady state were 28.8, For all 3 levomilnacipran ER doses, levomilnacipran unbound plasma ) % ( 80 levels exceeded the estimated IC values for 5-HT reuptake inhibition e 52.3, and 90.7 ng/mL for levomilnacipran ER 40, 80, and 120 mg/day, k a t p 60 respectively following multiple-dose administration (Figure 5) U c ifi c e p S 40 maintained for the entire 24-hour dosing period Table 1. Pharmacokinetic Parameters of Levomilnacipran ER Following a Multiple-Dose Administration Figure 5. Levomilnacipran Plasma Unbound Concentration 20 Compared With In Vitro 5-HT Reuptake Inhibition Valuesa 40 mg 80 mg 120 mg (n=37) (n=31) (n=32) 0 PK Parameter Mean ± SD Mean ± SD Mean ± SD 1.0E-11 1.0E-10 1.0E-09 1.0E-08 1.0E-07 1.0E-06 1.0E-05 1.0E-04 Concentration (M) Cmax, ng/mL 92.8 ± 29.3 180.4 ± 71.4 297.2 ± 98.1 IC90 a 5 Curves based on raw in vitro data from Auclair et al. ) 5 In vitro inhibition assays were performed using CHO cells stably expressing transfected hSERT or hNET as previously described. The raw in vitro M 100 γ b n IC80 data were curve fitted to construct inhibition curves using SigmaPlot (Ver 12.0) and the equation: y = min + (max-min)/(1 + [x/IC50] ) where x = Tmax, hours 6 (4, 24) 6 (2, 24) 6 (4, 10) ( levomilnacipran concentration, y = % of remaining actiity, min = minimal remaining activity; max = maximal remaining activity, n o IC50 = concentration at 50% inhibition, and γ = Hill slope. Concentrations at IC80 and IC90 were calculated based on parameters of the i t equation derived from the fitting. a r t IC AUC0-t, h*ng/mL 1519.8 ± 533.3 2722.2 ± 1327.4 4675.9 ± 1758.5 n 50 e c 10 n o c d C While levomilnacipran, duloxetine, and venlafaxine inhibit both 5-HT AUC0-τ, h*ng/mL 1519.8 ± 533.3 2934.9 ± 1171.9 4798.5 ± 1642.6 a m s a l and NE transport, the different pharmacological profiles of these P 1 Cmin, ng/mL 28.8 ± 17.8 52.3 ± 47.7 90.7 ± 56.8 40 mg/day compounds might have clinical significance 80 mg/day 120 mg/day c d Cave, ng/mL 63.3 ± 22.2 122.3 ± 48.8 199.9 ± 68.4 Venlafaxine and duloxetine showed higher potency for inhibiting the 0 0 5 10 15 20 25 serotonin transporter (SERT) versus the norepinephrine transporter aPatients with a series of plasma samples with evaluable PK parameters were included; b median (minimum, maximum); cn=28; dn=31. Time (h) AUC0-τ = area under the curve for plasma concentration versus time from time zero to dose-interval time τ; AUC0-t = area under the curve for plasma concentration versus time from time zero to time t; Cmax = maximum plasma concentration at steady state; C min = minimum plasma concentration at steady state; C ave = average a5-HT reuptake inhibition was estimated using in vitro data (CHO cells expressing hSERT) from Auclair et al.5 (NET); in contrast levomilnacipran shows preference for inhibiting NET plasma concentration at steady state; PK = pharmacokinetic; Tmax = time of maximum plasma concentration. relative to SERT (Figure 2) Similar dose-normalized Cmax and AUC0-τ Figure 2. Comparison of SNRIs at Serotonin Versus Norepinephrine Transportersa PK was linear and dose proportional following multiple-dose IC Ratio (Uptake) REFERENCES 50 oral administration of levomilnacipran ER in the dose range of 1. Nutt DJ. J Clin Psychiatry. 2008;69(suppl E1):4-7. 40-120 mg/day (Figure 3) 2. Blier P, Saint-Andre E, Hebert C, et al. Int J Neuropsychopharmacol. 2007;10(1):41-50. Venlafaxine 3. Stahl SM, Grady MM, Moret C, et al. CNS Spectr. 2005;10(9):732-747. Figure 3. Dose-Normalized Maximum Plasma Concentration (Cmax) 4. Bourdet DL, Tsuruda PR, Obedencio GP, et al. 2012;341(1):137-145. and Area Under the Curve (AUC0-τ) Values 5. Auclair AL, Martel JC, Assie MB, et al. Neuropharmacology. 2013;70:338-347. 6. Asnis GM, Bose A, Gommoll C, et al. J Clin Psychiatry. 2013;74(3):242-248. A. C B. AUC 7. Bakish D, Bose A, Gommoll C, et al. J Psychiatry Neurosci. 2014;39(1):40-49. Duloxetine max 0- 4 80 8. Sambunaris A, Bose A, Gommoll C, et al.
Load more

Recommended publications
  • Concomitant Drugs Associated with Increased Mortality for MDMA Users Reported in a Drug Safety Surveillance Database Isaac V
    www.nature.com/scientificreports OPEN Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database Isaac V. Cohen1, Tigran Makunts2,3, Ruben Abagyan2* & Kelan Thomas4 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug– drug interactions. The goal of this study was to evaluate the risks due to MDMA ingestion alone or in combination with other common medications and drugs of abuse using the FDA drug safety surveillance data. To date, nearly one thousand reports of MDMA use have been reported to the FDA. The majority of these reports include covariates such as co-ingested substances and demographic parameters. Univariate and multivariate logistic regression was employed to uncover the contributing factors to the reported risk of death among MDMA users. Several drug classes (MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, opioids), four antidepressants (bupropion, sertraline, venlafaxine and citalopram) and olanzapine demonstrated increased odds ratios for the reported risk of death. Future drug–drug interaction clinical trials should evaluate if any of the other drug–drug interactions described in our results actually pose a risk of morbidity or mortality in controlled medical settings. 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Adminis- tration (FDA) for the treatment of posttraumatic stress disorder (PTSD). During the past two decades, “ecstasy” was illegally distributed and is purported to contain MDMA, but because the market is unregulated this “ecstasy” may actually contain adulterants or no MDMA at all1.
    [Show full text]
  • Canadian Stroke Best Practice Recommendations
    CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS MOOD, COGNITION AND FATIGUE FOLLOWING STROKE Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression Update 2019 Lanctôt KL, Swartz RH (Writing Group Chairs) on Behalf of the Canadian Stroke Best Practice Recommendations Mood, Cognition and Fatigue following Stroke Writing Group and the Canadian Stroke Best Practice and Quality Advisory Committee, in collaboration with the Canadian Stroke Consortium © 2019 Heart & Stroke Heart and Stroke Foundation Mood, Cognition and Fatigue following Stroke Canadian Stroke Best Practice Recommendations Table 1C Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on selected classes of medications available for use in Canada and more commonly recommended for post-stroke depression. This table should be used as a reference guide by health care professionals when selecting an appropriate agent for individual patients. Patient compliance, patient preference and/or past experience, side effects, and drug interactions should all be taken into consideration during decision-making, in addition to other information provided in this table and available elsewhere regarding these medications. Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin–norepinephrine reuptake Other inhibitors (SNRI) Medication *citalopram – Celexa *duloxetine – Cymbalta methylphenidate – Ritalin (amphetamine)
    [Show full text]
  • Methylphenidate Hydrochloride
    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
    [Show full text]
  • Print Your Symptom Diary
    MEDICATION GUIDE FETZIMA® (fet-ZEE-muh) (levomilnacipran) extended-release capsules, for oral use What is the most important information I should know about FETZIMA? FETZIMA may cause serious side effects, including: • Increased risk of suicidal thoughts or actions in some children, adolescents, and young adults. FETZIMA and other antidepressant medicines may increase suicidal thoughts or actions in some children and young adults, especially within the first few months of treatment or when the dose is changed. FETZIMA is not for use in children. o Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression, bipolar illness (also called manic-depressive illness) or have a history of suicidal thoughts or actions. How can I watch for and try to prevent suicidal thoughts and actions? o Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. This is very important when an antidepressant medicine is started or when the dose is changed. o Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. o Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Call your healthcare provider or
    [Show full text]
  • Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 for Drugs Not Found on This List, Go to the Drug Search Engine At
    Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com *Exceptions as noted above* ▪ADHD Agents: Prior authorization required for participants under 6 years of age and participants 19 years of age and older ▪Spiriva AER 1.25mcg: Prior authorization NOT required for participants ages 6-17 years ▪Budesonide: Prior authorization NOT required for participants age 7 years and under ▪Anticonvulsants: Prior authorization NOT required for non-preferred epilepsy agents for those participants with a diagnosis of epilepsy or seizure disorder in Department records ▪Antipsychotics: Prior authorization required for participants under 8 years of age and long- term care residents 1 of 27 Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com Category Preferred Preferred, Requires PA Non-Preferred ADHD Agent - Amphetamine Mixtures* AMPHETAMINE/DEXTROAMPHETAMINE ADDERALL ADDERALL XR MYDAYIS ADHD Agent - Amphetamines* VYVANSE ADZENYS ER ADZENYS XR-ODT AMPHETAMINE SULFATE DESOXYN DEXEDRINE DEXTROAMPHETAMINE SULFATE DEXTROAMPHETAMINE SULFATE ER DYANAVEL XR EVEKEO EVEKEO ODT METHAMPHETAMINE HCL PROCENTRA ZENZEDI ADHD Agent - Selective Alpha Adrenergic Agonists CLONIDINE HCL ER INTUNIV CLONIDINE HYDROCHLORIDE ER GUANFACINE ER ADHD Agent - Selective Norepinephrine Reuptake Inhibitor* ATOMOXETINE ATOMOXETINE HYDROCHLORIDE STRATTERA 2 of 27 Preferred Drug List Illinois
    [Show full text]
  • Levomilnacipran (Fetzima®) Indication
    Levomilnacipran (Fetzima®) Indication: Indicated for the treatment of major depressive disorder (MDD), FDA approved July 2013. Mechanism of action Levomilnacipran, the more active enantiomer of racemic milnacipran, is a selective SNRI with greater potency for inhibition of norepinephrine relative to serotonin reuptake Compared with duloxetine or venlafaxine, levomilnacipran has over 10-fold higher selectivity for norepinephrine relative to serotonin reuptake inhibition The exact mechanism of the antidepressant action of levomilnacipran is unknown Dosage and administration Initial: 20 mg once daily for 2 days and then increased to 40 mg once daily. The dosage can be increased by increments of 40 mg at intervals of two or more days Maintenance: 40-120 mg once daily with or without food. Fetzima should be swallowed whole (capsule should not be opened or crushed) Levomilnacipran and its metabolites are eliminated primarily by renal excretion o Renal impairment Dosing: Clcr 30-59 mL/minute: 80 mg once daily Clcr 15-29 mL/minute: 40 mg once daily End-stage renal disease (ESRD): Not recommended Discontinuing treatment: Gradually taper dose, if intolerable withdrawal symptoms occur, consider resuming the previous dose and/or decrease dose at a more gradual rate How supplied: Capsule ER 24 Hour Fetzima Titration: 20 & 40 mg (28 ea) Fetzima: 20 mg, 40 mg, 80 mg, 120 mg Warnings and Precautions Elevated Blood Pressure and Heart Rate: measure heart rate and blood pressure prior to initiating treatment and periodically throughout treatment Narrow-angle glaucoma: may cause mydriasis. Use caution in patients with controlled narrow- angle glaucoma Urinary hesitancy or retention: advise patient to report symptoms of urinary difficulty Discontinuation Syndrome Seizure disorders: Use caution with a previous seizure disorder (not systematically evaluated) Risk of Serotonin syndrome when taken alone or co-administered with other serotonergic agents (including triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, and St.
    [Show full text]
  • Levomilnacipran for the Treatment of Major Depressive Disorder
    Out of the Pipeline Levomilnacipran for the treatment of major depressive disorder Matthew Macaluso, DO, Hala Kazanchi, MD, and Vikram Malhotra, MD An SNRI with n July 2013, the FDA approved levomil- Table 1 once-daily dosing, nacipran for the treatment of major de- Levomilnacipran: Fast facts levomilnacipran pressive disorder (MDD) in adults.1 It is I Brand name: Fetzima decreased core available in a once-daily, extended-release formulation (Table 1).1 The drug is the fifth Class: Serotonin-norepinephrine reuptake symptoms of inhibitor serotonin-norepinephrine reuptake inhibi- MDD and was well Indication: Treatment of major depressive tor (SNRI) to be sold in the United States disorder in adults tolerated in clinical and the fourth to receive FDA approval for FDA approval date: July 26, 2013 trials treating MDD. Availability date: Fourth quarter of 2013 Levomilnacipran is believed to be the Manufacturer: Forest Pharmaceuticals more active enantiomer of milnacipran, Dosage forms: Extended–release capsules in which has been available in Europe for 20 mg, 40 mg, 80 mg, and 120 mg strengths years and was approved by the FDA in Recommended dosage: 40 mg to 120 mg 2009 for treating fibromyalgia. Efficacy of capsule once daily with or without food levomilnacipran for treating patients with Source: Reference 1 MDD was established in three 8-week ran- domized controlled trials (RCTs).1 cial and occupational functioning in addi- Clinical implications tion to improvement in the core symptoms Levomilnacipran is indicated for treating of depression.5
    [Show full text]
  • Premium Non-Specialty Quantity Limit List January 2016
    Premium Non-Specialty Quantity Limit List January 2016 Therapeutic Category Drug Name Dispensing Limit Anti-infectives Antibiotics DIFICID (fidaxomicin) 200 mg 2 tabs/day & 10 days/30 days SIVEXTRO (tedizolid) Solr 6 vials/30 days SIVEXTRO (tedizolid) Tabs 6 tabs/30 days ZYVOX (linezolid) 28 tabs/30 days ZYVOX (linezolid) Suspension 4 bottles (600 mL)/28 days Antifungals LAMISIL (terbinafine) 250 mg 84 days supply/180 days Antimalarial QUALAQUIN (quinine) QL varies* Antivirals, Herpetic FAMVIR (famciclovir) 125 mg 1 tab/day FAMVIR (famciclovir) 250 mg 2 tabs/day FAMVIR (famciclovir) 500 mg 21 tabs/30 days SITAVIG (acyclovir) 50 mg 2 tabs/30 days VALTREX (valacyclovir) 1000 mg 3 tabs/day VALTREX (valacyclovir) 500 mg 2 tabs/day Antivirals, Influenza RELENZA (zanamivir) QL is 40 inh per 365 days. TAMIFLU (oseltamivir) 30 mg 40 caps per 365 days TAMIFLU (oseltamivir) 45 mg, 75 mg 20 caps per 365 days TAMIFLU (oseltamivir) Suspension 360 mL/365 days Cardiology Anticoagulants ELIQUIS (apixiban) 2 tabs/day ELIQUIS (apixiban) 5 mg 3 tabs/day IPRIVASK (desirudin) 35 days supply/180 days PRADAXA (dabigatran) 2 caps/day SAVAYSA (edoxaban) 1 tab/day XARELTO (rivaroxaban) 10 mg 35 days supply/180 days XARELTO (rivaroxaban) 15 mg 2 tabs/day XARELTO (rivaroxaban) 20 mg 1 tab/day XARELTO (rivaroxaban) Starter Pack 2 starter packs/year Heart Failure CORLANOR (ivabradine) 2 tabs/day Central Nervous System ADHD Agents ADDERALL (amphetamine/dextroamphetamine) 3 tabs/day ADDERALL XR (amphetamine/dextroamphetamine mixed salts) 1 cap/day APTENSIO XR (methylphenidate)
    [Show full text]
  • Sibutramine Hydrochloride Monohydrate) Capsule CS-IV
    MERIDIA - sibutramine hydrochloride capsule ---------- MERIDIA® (sibutramine hydrochloride monohydrate) Capsule CS-IV DESCRIPTION MERIDIA® (sibutramine hydrochloride monohydrate) is an orally administered agent for the treatment of obesity. Chemically, the active ingredient is a racemic mixture of the (+) and (-) enantiomers of cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, monohydrate, and has an empirical formula of C17H29Cl2NO. Its molecular weight is 334.33. The structural formula is shown below: Sibutramine hydrochloride monohydrate is a white to cream crystalline powder with a solubility of 2.9 mg/mL in pH 5.2 water. Its octanol: water partition coefficient is 30.9 at pH 5.0. Each MERIDIA capsule contains 5 mg, 10 mg, and 15 mg of sibutramine hydrochloride monohydrate. It also contains as inactive ingredients: lactose monohydrate, NF; microcrystalline cellulose, NF; colloidal silicon dioxide, NF; and magnesium stearate, NF in a hard-gelatin capsule [which contains titanium dioxide, USP; gelatin; FD&C Blue No. 2 (5- and 10-mg capsules only); D&C Yellow No. 10 (5- and 15-mg capsules only), and other inactive ingredients]. CLINICAL PHARMACOLOGY Mode of Action Sibutramine produces its therapeutic effects by norepinephrine, serotonin and dopamine reuptake inhibition. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. Pharmacodynamics Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin (5- hydroxytryptamine, 5-HT) and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo.
    [Show full text]
  • Pristiq (Desvenlafaxine Succinate) – First-Time Generic
    Pristiq® (desvenlafaxine succinate) – First-time generic • On March 1, 2017, Teva launched AB-rated generic versions of Pfizer’s Pristiq (desvenlafaxine succinate) 25 mg, 50 mg, and 100 mg extended-release tablets for the treatment of major depressive disorder. — Teva launched the 25 mg tablet with 180-day exclusivity. — In addition, Alembic/Breckenridge, Mylan, and West-Ward have launched AB-rated generic versions of Pristiq 50 mg and 100 mg extended-release tablets. — Greenstone’s launch plans for authorized generic versions of Pristiq 25 mg, 50 mg, and 100 mg tablets are pending. — Lupin and Sandoz received FDA approval of AB-rated generic versions of Pristiq 50 mg and 100 mg tablets on June 29, 2015. Lupin’s and Sandoz’s launch plans are pending. • Other serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder include desvenlafaxine fumarate, duloxetine, Fetzima™ (levomilnacipran), Khedezla™ (desvenlafaxine) , venlafaxine, and venlafaxine extended-release. • Pristiq and the other serotonin-norepinephrine reuptake inhibitors carry a boxed warning for suicidal thoughts and behaviors. • According to IMS Health data, the U.S. sales of Pristiq were approximately $883 million for the 12 months ending on December 31, 2016. optumrx.com OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com. All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.
    [Show full text]
  • A Brief Overview of Psychiatric Pharmacotherapy
    A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures • Some medications discussed are not approved by the FDA for use in the population discussed/described. • Some medications discussed are not approved by the FDA for use in the manner discussed/described. • Co-Owner: – PrairieCare and PrairieCare Medical Group – Catch LLC Disclaimer The contents of this handout are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical or psychiatric condition. Never disregard professional/medical advice or delay in seeking it because of something you have read in this handout. Material in this handout may be copyrighted by the author or by third parties; reasonable efforts have been made to give attribution where appropriate. Caveat Regarding the Role of Medication… Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. http://medicineworld.org/images/news-blogs/brain-700997.jpg Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. Neurotransmitter Receptor Source: National Institute on Drug Abuse Common Diagnoses and Associated Medications • Psychotic Disorders – Antipsychotics • Bipolar Disorders – Mood Stabilizers, Antipsychotics, & Antidepressants • Depressive Disorders – Antidepressants • Anxiety Disorders – Antidepressants & Anxiolytics • Attention Deficit Hyperactivity Disorder – Stimulants, Antidepressants, 2-Adrenergic Agents, & Strattera Classes of Medications • Anti-depressants • Stimulants and non-stimulant alternatives • Anti-psychotics (a.k.a.
    [Show full text]
  • Desvenlafaxine
    https://providers.amerigroup.com CONTAINS CONFIDENTIAL PATIENT INFORMATION desvenlafaxine Prior Authorization of Benefits (PAB) Form Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-512-9004 Provider Help Desk 1-800-454-3730 1. PATIENT INFORMATION 2. PHYSICIAN INFORMATION Patient Name: Prescribing Physician: Patient ID #: Physician Address: Patient DOB: Physician Phone #: Date of Rx: Physician Fax #: Patient Phone #: Physician Specialty: Patient Email Address: Physician DEA: Physician NPI #: Physician Email Address: 3. MEDICATION 4. STRENGTH 5. DIRECTIONS 6. QUANTITY PER 30 DAYS desvenlafaxine Specify: 7. DIAGNOSIS: 8. APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY NOTE: Any areas not filled out are considered not applicable to your patient & MAY AFFECT THE OUTCOME of this request. □ Yes □ No Documentation of a previous trial and therapy failure at a therapeutic dose with two preferred generic SSRIs* has been provided If No: □ Yes □ No Documented evidence is provided that the use of these agents would be medically contraindicated □ Yes □ No Documentation of a previous trial and therapy failure at a therapeutic dose with one preferred generic SNRI** has been provided If No: □ Yes □ No Documented evidence is provided that the use of these agents would be medically contraindicated □ Yes □ No Documentation of a previous trial and therapy failure at a therapeutic dose with one non-SSRI/SNRI generic antidepressant** has been provided If No: □ Yes □ No Documented evidence is provided that the use of these
    [Show full text]